A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Korsana Biosciences, Inc. develops therapeutic antibodies for the treatment of neurodegenerative diseases. The company has developed Therapeutic Targeting (THETA), a blood-brain barrier-penetrant shuttle platform designed to enhance central nervous system exposure of investigational therapies and enable delivery of large therapeutic molecules across the blood-brain barrier into the central nervous system. The company advances a pipeline of THETA-enabled therapeutics with an initial focus on neurodegenerative disorders. Its lead product candidate is KRSA-028, an anti-amyloid beta antibody for the treatment of Alzheimer's disease, which combines the THETA platform with elements of anti-amyloid beta approaches and targets a clinically relevant form of amyloid beta designed to improve brain uptake while reducing effects on reticulocytes. The company is also advancing a pipeline of additional THETA-enabled therapies for other neurodegenerative diseases. Korsana Biosciences, Inc. was incorporated in 2024 and is based in Waltham, Massachusetts.
Financial Summary
| Share Statistics | KRSA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,593.0 | $271.9 | 51% |
|
| Shares Out (Mil) | 5.0 | 54.2 | 14% |
|
| Institutional Ownership | 97.4% | 92.9% | 74% |
|
| Float (Mil) | 41.9 | 42.1 | 43% |
|
| Beta | na | 0.95 | na |
|
| Avg Daily Volume (000s) | 50 | 612 | 28% |
|
| Price Change (52-week) |
110.0% | 56.0% | 94% |
|
| Growth | KRSA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.1% | na |
|
| Net Income (5yr) | na | (10.1%) | na |
|
| EPS (5yr) | na | 15.7% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.6%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | KRSA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($49) | ($43) | 16% |
|
| EPS (TTM) | ($13.371) | ($1.500) | 4% |
|
| Operating Cash Flow (TTM) (Mil) | ($42) | ($32) | 11% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $1 | $4 | 17% |
|
| Enterprise Value (Q1) (Mil) | $1,636 | $177 | 46% |
|
| Valuation | KRSA | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.67 | na |
|
| P/E | na | 19.5 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | KRSA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 69.0% | na |
|
| Net Margin | na | (71.5%) | na |
|
| ROA | (71.3%) | (47.4%) | 8% |
|
| ROE | 208.7% | (54.6%) | 98% |
|
| Liabilities to Assets | 6.7% | 29.3% | 4% |
|
| F-Score | 1 | 3 | na |
|
Korsana Biosciences, Inc. did not pass any screens on 9/22/2026.
